Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

Contact Us

Search

galactosemia

Neuroscience

Neuroscience Today — December 17, 2025

This week’s Neuroscience update features regulatory decisions, pipeline…

Rare Disease news

Rare Disease Today—November 27, 2025

This week’s rare diseases update spotlights key developments, regulatory…

Categories

Obesity News
Endocrinology News
Our Insights
Immunology News
Case studies
Hematology News
BioPharma and Tech News
Oncology News
BioPharma Strategy, CI and AI Guides
Lucid Diligence Brief
Conference Social Media Reports
Venture Capital
AI in Healthcare and Digital Health
Conference Previews
Cell and Gene Therapy News
Rare Disease News
Neuroscience News
Women's Health News
Public Health News
Respiratory News
Cardiovascular News
Vaccine news

Recent Posts

Public Health Today—16 January, 2026
Respiratory Today—January 16, 2026
Vaccines Today—January 16, 2026
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy
Cardiovascular Video Recap—January 15, 2026

Tags

AACR 2025 ACC 2025 ailux ALX Oncology Anavex Life Sciences arrhythmias cholera clinical validation compassionate use device pathways Dual agonist therapy EASD25 gefurulimab geneventiv therapeutics graft-versus-host disease Hemgenix Huons INHALE 1 study ITM Isotope Technologies Munich ivc thrombectomy LUMC Major depressive disorder mavacamten MFDS mursla bio nvidia OBODENCE OCRA OpenEvidence PARADIGM perioperative therapy Pluristyx ProFound Therapeutics Rare endocrine disorders rosacea Rubraca Stem-cell diabetes therapy Surgical retina T-cell engager Taho Pharmaceuticals Taysha Gene Therapies TCT tocilizumab-anoh YAP signaling Zika vaccine

Archives

Archives

LucidQuest Ventures

Accelerate Your Success

LATEST NEWS

Public Health Today—16 January, 2026
Respiratory Today—January 16, 2026
Vaccines Today—January 16, 2026
Lucid Diligence Brief: Ocugen preliminary Phase 2 data in geographic atrophy
Cardiovascular Video Recap—January 15, 2026

TAGS

AACR 2025 ACC 2025 ailux ALX Oncology Anavex Life Sciences arrhythmias cholera clinical validation compassionate use device pathways Dual agonist therapy EASD25 gefurulimab geneventiv therapeutics graft-versus-host disease Hemgenix Huons INHALE 1 study ITM Isotope Technologies Munich ivc thrombectomy LUMC Major depressive disorder mavacamten MFDS mursla bio nvidia OBODENCE OCRA OpenEvidence PARADIGM perioperative therapy Pluristyx ProFound Therapeutics Rare endocrine disorders rosacea Rubraca Stem-cell diabetes therapy Surgical retina T-cell engager Taho Pharmaceuticals Taysha Gene Therapies TCT tocilizumab-anoh YAP signaling Zika vaccine

Consulting Services
For Investors
- Lucid Diligence Briefs
- Venture Capital
Case Studies
Insights
- Conference Previews
- Conference Social Media Reports
LucidWargames
QuickAnswers
LucidSearch
BioPharma and Tech News

© 2026 LucidQuest Ventures. All rights reserved

We use cookies from third party services to offer you a better experience. Read about how we use cookies and how you can control them by clicking "Privacy Preferences".

Privacy Preference Center

Privacy Preferences

When you visit any website, it may store or retrieve information on your browser in the form of cookies. Since we respect your right to privacy, you can choose not to permit data collection from certain types of services. However, not allowing these services may impact your experience ans we are able to offer you.

Privacy Policy

Required

You read and agreed to our Privacy Policy

Tracking

We use third-party cookies that help us analyze and understand how you use this website. These cookies do not store any personal information.

Privacy Policy